Dublin, Feb. 19, 2026 (GLOBE NEWSWIRE) -- The "Pipeline of Complement C5 Inhibitors & C5 Receptor Antagonists" report has been added to ResearchAndMarkets.com's offering. This competitive intelligence ...

The Nature Index 2025 Research Leaders — previously known as Annual Tables — reveal the leading institutions and countries/territories in the natural and health sciences, according to their output in ...

Expert panelists evaluate results regarding complement inhibitor trials for utilization in PNH management. Several complement inhibitors have been approved since eculizumab, including ravulizumab, a ...

A research team at the Medical University of South Carolina reports in Cells that the complement system, part of the body's natural immune defenses, is a key driver of inflammatory responses that ...

The results of a newly reported study may offer scientists a strategy for mitigating the negative side effects associated with intravenous injection of nanoparticles used in medicine. The new approach ...

Annexon, Inc. (ANNX) was able to achieve positive results from its phase 3 study for the treatment of patients with Guillain-Barré syndrome [GBS]. Matter of fact, it noted that a lower dose of its ...

The figure focuses on complement activation by means of the alternative pathway because it is the one responsible for hemolysis in PNH. The lightning bolt symbolizes the spontaneous hydrolytic ...

SAN FRANCISCO -- Investigational gefurulimab met its primary efficacy endpoint in adults with anti-acetylcholine receptor (AChR) antibody-positive generalized myasthenia gravis (MG), topline data from ...

The treatment pipeline for generalized myasthenia gravis (gMG) continues to be active, a consequence of the ongoing progress in knowledge that led to approval of six new drugs for the disease. In ...

Among people with sickle cell disease—an inherited blood disorder—acute chest syndrome (ACS) is the leading cause of death. The condition is the result of red blood cells becoming stiff, sticky, and ...